UTHR

United Therapeutics Corporation

Healthcare · $20.2B market cap

Share price

$541.70

close of Oct 3, 2026

Fair value

$493.31

Sticker Price

Payback Price

$197.32

buy price

Fairly Valued

UTHR is Fairly Valued: at $541.70 it's within 10% of its fair value of $493.31. Its buy price (Payback Price) is $197.32, 64% below today's price. Business quality is strong: all 5 key numbers clear the 10% bar.

How we valued it

Justified P/B (Financials). It has earned a steady return on its equity for years, and its tangible assets are worth 29% of its share price. For a business like that, book value and the return on it are a sturdier guide than an earnings forecast.

Business quality

5 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth13.7% a year✓

Equity per share growth17.2% a year✓

Sales growth11.5% a year✓

Free cash flow growth11.5% a year✓

Return on invested capital15.0%✓

Follow UTHR

Get notified when it reaches its buy price of $197.32. Free.

Create a free account

Superinvestors

None of the investors we track holds UTHR right now. In Q2 2026, 1 sold out. Who we track

Moves in Q2 2026

Sold out: Mairs & Power Funds

Insider activity

Since Sep 2, 2026: no open-market purchases, 92 sales worth $32.2M and 8 other filings (stock awards, tax withholding and similar). Why purchases matter

Sales

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-10

Sold

$142K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-10

Sold

$142K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-10

Sold

$304K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-10

Sold

$355K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-10

Sold

$291K

Show all 92 sales

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-10

Sold

$772K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-10

Sold

$1.1M

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-10

Sold

$687K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-10

Sold

$894K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-10

Sold

$60K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-09

Sold

$102K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-09

Sold

$257K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-09

Sold

$402K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-09

Sold

$443K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-09

Sold

$487K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-09

Sold

$576K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-09

Sold

$511K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-09

Sold

$181K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-09

Sold

$259K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-09

Sold

$200K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-09

Sold

$80K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-09

Sold

$635K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-09

Sold

$596K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-09

Sold

$40K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-08

Sold

$211K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-08

Sold

$353K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-08

Sold

$586K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-08

Sold

$612K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-08

Sold

$587K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-08

Sold

$508K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-08

Sold

$948K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-08

Sold

$149K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-08

Sold

$127K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-08

Sold

$297K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-08

Sold

$71K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-08

Sold

$69K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-08

Sold

$108K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-08

Sold

$97K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-08

Sold

$19K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-04

Sold

$157K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-04

Sold

$569K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-04

Sold

$742K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-04

Sold

$1.7M

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-04

Sold

$1.4M

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-04

Sold

$109K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-04

Sold

$19K

MAHON PAUL A

EVP & GENERAL COUNSEL · 2026-09-03

Sold

$157K

MAHON PAUL A

EVP & GENERAL COUNSEL · 2026-09-03

Sold

$5K

MAHON PAUL A

EVP & GENERAL COUNSEL · 2026-09-03

Sold

$82K

MAHON PAUL A

EVP & GENERAL COUNSEL · 2026-09-03

Sold

$291K

MAHON PAUL A

EVP & GENERAL COUNSEL · 2026-09-03

Sold

$463K

MAHON PAUL A

EVP & GENERAL COUNSEL · 2026-09-03

Sold

$97K

MAHON PAUL A

EVP & GENERAL COUNSEL · 2026-09-03

Sold

$77K

MAHON PAUL A

EVP & GENERAL COUNSEL · 2026-09-03

Sold

$505K

MAHON PAUL A

EVP & GENERAL COUNSEL · 2026-09-03

Sold

$1.1M

MAHON PAUL A

EVP & GENERAL COUNSEL · 2026-09-03

Sold

$449K

MAHON PAUL A

EVP & GENERAL COUNSEL · 2026-09-03

Sold

$740K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-03

Sold

$21K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-03

Sold

$461K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-03

Sold

$1.5M

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-03

Sold

$784K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-03

Sold

$697K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-03

Sold

$200K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-03

Sold

$116K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-03

Sold

$39K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-03

Sold

$193K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-03

Sold

$289K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-03

Sold

$211K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-03

Sold

$96K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Sold

$41K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Sold

$20K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Sold

$20K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Sold

$101K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Sold

$60K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Sold

$80K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Sold

$27K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Sold

$270K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Sold

$181K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Sold

$386K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Sold

$210K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Sold

$257K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Sold

$257K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Sold

$1.0M

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Sold

$901K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Sold

$275K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Sold

$117K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Sold

$78K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Sold

$58K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Sold

$39K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Sold

$77K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Sold

$77K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Sold

$57K

Other filings

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-10

Option exercise

$1.1M

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-09

Option exercise

$1.1M

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-08

Option exercise

$1.1M

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-04

Option exercise

$1.1M

MAHON PAUL A

EVP & GENERAL COUNSEL · 2026-09-03

Option exercise

$1.2M

Show all 8 other filings

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-03

Option exercise

$69K

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-03

Option exercise

$1.2M

ROTHBLATT MARTINE A

Chairperson & CEO · 2026-09-02

Option exercise

$1.3M

About United Therapeutics Corporation

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works

Verdict

How we valued it

Business quality

Superinvestors

Insider activity

Sales

Other filings

About United Therapeutics Corporation